AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

As Amarin’s Vascepa recently became the first fish oil-derived drug approved to cut heart risks, AstraZeneca was eager to show its Epanova could do the same. Now, that hope has died. The drug's cardiovascular outcomes trial came up empty, giving Vascepa a clearer shot at blockbuster sales—and costing AstraZeneca at least $100 million.